8-K: Intensity Therapeutics Reports 2025 Results, Clinical Progress

Intensity Therapeutics announced its 2025 year-end financial results, highlighting clinical advancements for INT230-6 and an extended cash runway into Q2 2027.

Summary

• Reported 2025 year-end financial results, with a net loss of $11.6 million, an improvement from $16.3 million in 2024.
• Raised over $20 million in gross proceeds in 2025, resulting in $11.9 million in cash and cash equivalents as of December 31, 2025.
• Extended the company's cash runway into the second quarter of 2027.
• The IT-01 Study manuscript for INT230-6 in 64 refractory metastatic cancer patients was published in eBioMedicine, reporting a 75% disease control rate and median overall survival of 11.9 months.
• Preliminary observations from the INVINCIBLE-4 Study in triple negative breast cancer (TNBC) showed 71.4% pathological complete response (pCR) in patients receiving INT230-6 prior to standard of care (SOC) compared to 33% in the SOC alone arm.
• The INVINCIBLE-4 Study also observed 44% fewer grade 3 or higher adverse events in the INT230-6 + SOC cohort.
• Full approval was granted on March 26, 2026, to resume enrollment for the INVINCIBLE-4 Study.
• The INVINCIBLE-3 Study (Phase 3 for soft tissue sarcoma) paused new site activations and patient enrollments in March 2025 due to funding constraints, with 21 patients enrolled prior to the pause.
• Research and development expenses decreased to $6.8 million in 2025 from $10.5 million in 2024, primarily due to lower INVINCIBLE-3 Study costs and no new manufacturing batches of INT230-6.
• General and administrative expenses decreased to $5.2 million in 2025 from $6.1 million in 2024, driven by lower stock-based compensation and cost efficiencies.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, driven by promising clinical trial results and a strengthened balance sheet with an extended cash runway. However, the pause in the INVINCIBLE-3 Phase 3 study due to funding constraints introduces a notable element of risk and uncertainty.

Positives

• Successfully raised over $20 million in gross proceeds in 2025, strengthening the balance sheet.
• Extended the current operating cash runway into the second quarter of 2027.
• IT-01 Study data published in eBioMedicine showed a 75% disease control rate and median overall survival of 11.9 months in heavily pretreated metastatic cancer patients, comparing favorably to historical phase 1/2 studies (4-7 months mOS).
• Median overall survival in a metastatic sarcoma subset receiving INT230-6 was 21.3 months.
• Exploratory analysis in IT-01 showed significantly improved disease control rate (83.3% vs 50%) and median overall survival (18.7 months vs 3.1 months) when greater than 40% of total tumor burden was treated.
• Observed abscopal effects (shrinkage of uninjected tumors) in approximately 20% of patients in the >40% TTB group of the IT-01 study.
• INT230-6 monotherapy in IT-01 showed no dose-limiting toxicities and a favorable safety profile with no grade 4 or 5 treatment-related adverse events.
• Preliminary INVINCIBLE-4 Study results showed favorable efficacy with 71.4% pCR in the INT230-6 + SOC arm compared to 33% in the SOC alone arm for TNBC patients.
• INVINCIBLE-4 Study reported 44% fewer grade 3 or higher adverse events in the INT230-6 + SOC arm.
• Full approval to resume enrollment for the INVINCIBLE-4 Study was granted on March 26, 2026.
• Net loss decreased to $11.6 million in 2025 from $16.3 million in 2024, indicating improved financial performance.
• Reduced research and development and general and administrative expenses due to cost efficiencies.

Negatives

• New site activations and patient enrollments in the INVINCIBLE-3 Study were paused in March 2025 due to funding constraints.
• The company continues to incur a net loss, totaling $11.6 million for the year ended December 31, 2025.
• Reinitiating patient enrollment and site activations for the INVINCIBLE-3 Study is contingent on obtaining sufficient funding.

Risks

• The need to raise additional funding before the company can expect to generate any revenues from product sales.
• Risks and uncertainties related to the initiation, timing, progress, and results of future preclinical studies and clinical trials and research and development programs.
• The possibility that product candidates appearing promising in early research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials.
• Uncertainty regarding the timing or likelihood of regulatory filings and approvals.
• The ability to maintain and establish collaborations or obtain additional funding.
• Potential inability to satisfy the Nasdaq Capital Market's requirements for continued listing, which could lead to delisting.
• Actual results may differ materially from forward-looking statements due to various factors, including those described in the Risk Factors section of the company's Annual Report on Form 10-K.

Future Outlook

The company intends to resume patient enrollment in both the INVINCIBLE-3 and INVINCIBLE-4 studies as soon as possible, contingent on obtaining sufficient funding. More detailed results for the seven Cohort A patients from the INVINCIBLE-4 Study are expected to be presented at a future oncology conference. The current operating cash runway extends into the second quarter of 2027.

Management Comments

• Lewis H. Bender, Founder, President, and CEO, stated, "Our data published in the Lancets eBioMedicine journal for the treatment of metastatic disease, and the results reported on the safety and efficacy in the INVINCIBLE-4 study were promising and unique for a locally-delivered oncology drug."
• Lewis H. Bender also commented, "With the capital raised in 2025 and an unused $60 million ATM facility in place, we intend to resume patient enrollment in both studies as soon as possible."
• Lewis H. Bender emphasized, "Intensity remains committed to helping patients live longer, healthier lives with less toxicity."
• Lewis H. Bender noted, "The ACS data supports the conclusion that todays cancer treatments have many limitations, and that the unmet medical need for new ideas and better cancer therapies remains as strong as ever."

Industry Context

StockSavvy.ai notes that the reported clinical data for INT230-6, particularly the median overall survival of 11.9 months in heavily pretreated metastatic cancer patients and 21.3 months in metastatic sarcoma, compares favorably to historical phase 1/2 studies (4-7 months mOS). This suggests a potential differentiation for Intensity's intratumoral approach in a competitive oncology landscape, especially given the high unmet need highlighted by the American Cancer Society's increasing cancer death estimates. The focus on triple-negative breast cancer and soft tissue sarcoma addresses difficult-to-treat indications.

Comparison to Industry Standards

• The median overall survival (mOS) of 11.9 months for INT230-6 in heavily pretreated metastatic cancer patients compares favorably to historical phase 1/2 studies that typically reported an mOS of 4 to 7 months.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical data and extended cash runway, but also risk from the paused Phase 3 trial and the need for future funding, which could lead to further dilution.
• Patients: Continued access to INT230-6 for enrolled patients in INVINCIBLE-3. Potential for new patients to enroll in INVINCIBLE-4 and eventually INVINCIBLE-3 if funding is secured, offering a novel treatment option for difficult cancers.
• Employees: Continued operations supported by the extended cash runway, but uncertainty regarding the pace of clinical development could impact morale.
• Creditors/Suppliers: Improved financial stability with increased cash, reducing immediate credit risk.

Next Steps

• Resume patient enrollment and site activations for the INVINCIBLE-3 Study once sufficient funding is obtained.
• Present more detailed results for the seven Cohort A patients from the INVINCIBLE-4 Study at a future oncology conference.
• Continue to treat all patients enrolled in the INVINCIBLE-3 Study in cooperation with third-party contract research organizations.

Key Dates

Recommendation

While the clinical data for INT230-6 is promising, particularly the favorable survival rates and disease control, and the company has extended its cash runway, the pause in the Phase 3 INVINCIBLE-3 study due to funding constraints introduces significant uncertainty. The company's ability to secure additional funding to restart this pivotal trial is critical for its long-term success. Investors should hold to monitor progress on securing funding and the reinitiation of the Phase 3 trial, as well as further data from INVINCIBLE-4. The potential for future dilution from the ATM facility also warrants caution.

Keywords

Intensity Therapeutics, INTS, oncology, cancer therapy, INT230-6, intratumoral, clinical trials, biotechnology, metastatic cancer, triple negative breast cancer, soft tissue sarcoma, DfuseRx, financial results, cash runway, SEC filing, 8-K